drugset
drugset / Trial / NCT03464032

A Study of BCD-135 in Patients With Advanced Solid Tumors

NCT03464032 ↗

Phase 1 Unknown 30 enrolled Biocad
NaSingle-groupOpen-labelTreatment

Summary

A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-135 (JSC BIOCAD, Russia) in Patients with Advanced Solid Tumors

Timeline

Start
2017-10-31
Primary completion
2018-05-31
Completion
2018-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject MANELIMAB Monoclonal antibody 0.4 mg/kg —
Subject MANELIMAB Monoclonal antibody 1 mg/kg —
Subject MANELIMAB Monoclonal antibody 3 mg/kg —
Subject MANELIMAB Monoclonal antibody 10 mg/kg —
Subject MANELIMAB Monoclonal antibody 20 mg/kg —

Indications

melanoma non-small cell lung carcinoma renal cell carcinoma urinary bladder cancer